Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple combination therapy of amlodipine + valsartan + rosuvastatin in patients with dyslipidemia and hypertension
KCT0003475Phase 3Completed
- Sponsor
- Kyungdong Pharmaceutical
- Start
- Dec 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of amlodipine, valsartan, rosuvastatin in hypertension (HTN), dyslipidemia, sponsored by Kyungdong Pharmaceutical. Started Dec 2017; status: completed.
02
Drugs
amlodipinevalsartanrosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on KCT0003475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003475.